Online survey of patients with progressive fibrosing interstitial lung disease (PF-ILD) in Japan - A study of physician and patient experiences and perceptions of the course of treatment from initial symptom onset to the time of the survey -

Online survey of patients with progressive fibrosing interstitial lung disease (PF-ILD) in Japan - A study of physician and patient experiences and perceptions of the course of treatment from initial symptom onset to the time of the survey - - Online survey of patients with progressive fibrosing interstitial lung disease (PF-ILD) in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050411

Enrollment

120

Registered

2023-02-22

Start date

2023-01-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive fibrosing interstitial lung disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: <Inclusion criteria for physicians> 1) Physicians who are engaged in medical treatment at medical institutions in Japan 2) Physicians with sufficient experience in treating patients with PF-ILD 3) Physicians who have agreed with the objective of the study and provided informed consent of their own free will by themselves electromagnetically on the website for answering the physician questionnaire and requesting questionnaires to multiple patients <Inclusion criteria for patients> 1) Patients aged 18 years or older (regardless of gender) 2) Patients with a confirmed diagnosis of PF-ILD and continuing treatment (regardless of whether the patient is an outpatient or inpatient) 3) Patients who have been informed by their physician that they have PF-ILD 4) Patients who can provide information before and after the start of treatment for PF-ILD (within approximately 12 months after the start of treatment for PF-ILD) 5) Patients who can understand Japanese 6) Patients who can access the website and complete the questionnaire 7) Patients who have carefully read the explanatory document regarding this study and have given informed consent of their own free will by themselves electromagnetically on the website to participate in this study

Exclusion criteria

Exclusion criteria: <Exclusion criteria for physicians> Not applicable <Exclusion criteria for patients> 1) Patients with a confirmed diagnosis of IPF

Design outcomes

Primary

Measure	Time frame
1) Information on patient backgrounds, disease, treatment experience and awareness of patients with PF-ILD obtained from the physician questionnaire survey 2) Information on patient backgrounds, disease, treatment experience and perceptions of patients with PF-ILD obtained from the patient questionnaire survey	—

Countries

Japan

Contacts

Public ContactTomoo Okamura

Nippon Boehringer Ingelheim Co., Ltd. Specialty Care Medicine, Medicine Division

tomoo.okamura@boehringer-ingelheim.com03-6417-2444

Outcome results